by | Jul 10, 2024 | Publications
JCO Precis Oncol. 2024 Jul;8:e2300613. doi: 10.1200/PO.23.00613. ABSTRACT PURPOSE: Given the high heterogeneity in survival for patients with multiple myeloma, it would be clinically useful to quantitatively predict the individual survival instead of attributing...
by | Jul 10, 2024 | Publications
Front Ophthalmol (Lausanne). 2022 Mar 30;2:849343. doi: 10.3389/fopht.2022.849343. eCollection 2022. ABSTRACT Multiple myeloma (MM) is the second most common hematologic malignancy and most common primary bone malignancy. Ocular manifestations of MM are extremely rare...
by | Jul 10, 2024 | Publications
Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024062. doi: 10.4084/MJHID.2024.062. eCollection 2024. ABSTRACT Multiple myeloma (MM) is a disorder of the monoclonal plasma cells and is the second most common hematologic malignancy. MM initiation and progression are...
by | Jul 10, 2024 | Publications
Cas Lek Cesk. 2024;163(3):98-105. ABSTRACT The incidence of monoclonal gammopathy (MG) increases with age. In individuals over 80 years of age, we can diagnose the presence of monoclonal immunoglobulin (MIg) in up to 10 % of cases. Not only malignant diseases such as...
by | Jul 10, 2024 | Publications
Br J Haematol. 2024 Jun 21. doi: 10.1111/bjh.19612. Online ahead of print. ABSTRACT There are limited data on the optimal choice of anticoagulation in multiple myeloma (MM) patients receiving immunomodulatory drugs (IMiDs). We conducted a propensity score-matched...
by | Jul 10, 2024 | Publications
Nat Commun. 2024 Jul 9;15(1):5767. doi: 10.1038/s41467-024-50073-x. ABSTRACT Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells in the bone marrow. MM patients with aggressive progression have poor survival,...
